Kenneth K Mugwanya1,2, Jared M Baeten1,3, Christina Wyatt4, Nelly R Mugo1,5, Connie L Celum1,3, Allan Ronald6, John Kiarie7, Elly Katabira8, Renee Heffron1. 1. Department of Global Health, University of Washington, Seattle, WA. 2. Division of Disease Control, School of Public Health, Makerere University, Kampala, Uganda. 3. Medicine, University of Washington, Seattle, WA. 4. Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY. 5. Kenya Medical Research Institute, Nairobi, Kenya. 6. Department of Medicine, University of Manitoba, Winnipeg, Canada. 7. Department of Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya. 8. Department of Medicine, Makerere University, Kampala, Kenya.
Abstract
BACKGROUND: Wide-scale implementation of oral tenofovir-based pre-exposure prophylaxis (PrEP) for HIV prevention is now policy in many settings. However, the optimal frequency for monitoring kidney function remains uncertain. We investigated the impact of 6-monthly compared with 3-monthly creatinine clearance (CrCl) monitoring on the identification of moderate kidney dysfunction, defined as CrCl <60 mL/min. METHODS: Data were from 2 prospective daily oral PrEP studies in Kenya and Uganda: the Partners PrEP Study, a randomized safety, and efficacy trial of PrEP that conducted 3-monthly CrCl monitoring (n = 4404) and the Partners Demonstration Project (n = 954), an open-label delivery study of PrEP that used 6-monthly monitoring. CrCl ≥60 mL/min was required for enrollment in both studies. Abnormal results were followed with confirmatory testing within approximately 1 week. Follow-up was for up to 24 months. RESULTS: Of 5358 participants included in the analysis, 87% were younger than 45 years, a third were female, and 21% had a baseline CrCl between 60 and 90 mL/min. Confirmed CrCl <60 mL/min events were rare, occurring in 52 individuals (<1%) in 24 months. The 12-month cumulative proportion of persons with CrCl <60 mL/min was 0.2% with 3-monthly screening and 0.5% with 6-monthly screening. Older age (>45 years), lower weight (<55 kg), elevated blood pressure (>140 mm Hg), and baseline CrCl between 60 and 90 mL/min were independently associated with CrCl decline <60 mL/min during follow-up. CONCLUSIONS: In these 2 PrEP studies, with generally young participants, the occurrence and pattern of clinically relevant decline in CrCl were not qualitatively different based on 3- or 6-monthly CrCl monitoring schedule. These data suggest that for most persons receiving PrEP for up to 24 months, less frequent CrCl monitoring would be safe and reduce required expenditures for repeat confirmatory testing.
RCT Entities:
BACKGROUND: Wide-scale implementation of oral tenofovir-based pre-exposure prophylaxis (PrEP) for HIV prevention is now policy in many settings. However, the optimal frequency for monitoring kidney function remains uncertain. We investigated the impact of 6-monthly compared with 3-monthly creatinine clearance (CrCl) monitoring on the identification of moderate kidney dysfunction, defined as CrCl <60 mL/min. METHODS: Data were from 2 prospective daily oral PrEP studies in Kenya and Uganda: the Partners PrEP Study, a randomized safety, and efficacy trial of PrEP that conducted 3-monthly CrCl monitoring (n = 4404) and the Partners Demonstration Project (n = 954), an open-label delivery study of PrEP that used 6-monthly monitoring. CrCl ≥60 mL/min was required for enrollment in both studies. Abnormal results were followed with confirmatory testing within approximately 1 week. Follow-up was for up to 24 months. RESULTS: Of 5358 participants included in the analysis, 87% were younger than 45 years, a third were female, and 21% had a baseline CrCl between 60 and 90 mL/min. Confirmed CrCl <60 mL/min events were rare, occurring in 52 individuals (<1%) in 24 months. The 12-month cumulative proportion of persons with CrCl <60 mL/min was 0.2% with 3-monthly screening and 0.5% with 6-monthly screening. Older age (>45 years), lower weight (<55 kg), elevated blood pressure (>140 mm Hg), and baseline CrCl between 60 and 90 mL/min were independently associated with CrCl decline <60 mL/min during follow-up. CONCLUSIONS: In these 2 PrEP studies, with generally young participants, the occurrence and pattern of clinically relevant decline in CrCl were not qualitatively different based on 3- or 6-monthly CrCl monitoring schedule. These data suggest that for most persons receiving PrEP for up to 24 months, less frequent CrCl monitoring would be safe and reduce required expenditures for repeat confirmatory testing.
Authors: Kenneth K Mugwanya; Christina Wyatt; Connie Celum; Deborah Donnell; James Kiarie; Allan Ronald; Jared M Baeten Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: Monica Gandhi; David V Glidden; Kenneth Mayer; Mauro Schechter; Susan Buchbinder; Beatriz Grinsztejn; Sybil Hosek; Martin Casapia; Juan Guanira; Linda-Gail Bekker; Alexander Louie; Howard Horng; Leslie Z Benet; Albert Liu; Robert M Grant Journal: Lancet HIV Date: 2016-08-31 Impact factor: 12.767
Authors: Susan P Buchbinder; David V Glidden; Albert Y Liu; Vanessa McMahan; Juan V Guanira; Kenneth H Mayer; Pedro Goicochea; Robert M Grant Journal: Lancet Infect Dis Date: 2014-03-07 Impact factor: 25.071
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Kenneth Mugwanya; Jared Baeten; Connie Celum; Deborah Donnell; Thomas Nickolas; Nelly Mugo; Andrea Branch; Jordan Tappero; James Kiarie; Allan Ronald; Michael Yin; Christina Wyatt Journal: J Infect Dis Date: 2016-03-29 Impact factor: 5.226
Authors: Jared M Baeten; Deborah Donnell; Nelly R Mugo; Patrick Ndase; Katherine K Thomas; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Lara Kidoguchi; Robert W Coombs; Craig Hendrix; Mark A Marzinke; Lisa Frenkel; Jessica E Haberer; David Bangsberg; Connie Celum Journal: Lancet Infect Dis Date: 2014-10-07 Impact factor: 25.071
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Sarah Masyuko; Irene Mukui; Olivia Njathi; Maureen Kimani; Patricia Oluoch; Joyce Wamicwe; Jane Mutegi; Susan Njogo; Micah Anyona; Phillip Muchiri; Lucy Maikweki; Helgar Musyoki; Prince Bahati; Jordan Kyongo; Tom Marwa; Elizabeth Irungu; Michael Kiragu; Urbanus Kioko; Justus Ogando; Dan Were; Kigen Bartilol; Martin Sirengo; Nelly Mugo; Jared M Baeten; Peter Cherutich; On Behalf Of The PrEP Technical Working Group Journal: Sex Health Date: 2018-11 Impact factor: 2.706
Authors: Eric C Tang; Eric Vittinghoff; Peter L Anderson; Stephanie E Cohen; Susanne Doblecki-Lewis; Oliver Bacon; Megan E Coleman; Susan P Buchbinder; Wairimu Chege; Michael A Kolber; Richard Elion; Michael Shlipak; Albert Y Liu Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731
Authors: Renee Heffron; Kenneth Ngure; Josephine Odoyo; Nulu Bulya; Edna Tindimwebwa; Ting Hong; Lara Kidoguchi; Deborah Donnell; Nelly R Mugo; Elizabeth A Bukusi; Elly Katabira; Stephen Asiimwe; Jennifer Morton; Susan Morrison; Harald Haugen; Andrew Mujugira; Jessica E Haberer; Norma C Ware; Monique A Wyatt; Mark A Marzinke; Lisa M Frenkel; Connie Celum; Jared M Baeten Journal: Gates Open Res Date: 2018-01-30
Authors: D Allen Roberts; Ruanne V Barnabas; Felix Abuna; Harison Lagat; John Kinuthia; Jillian Pintye; Aaron F Bochner; Steven Forsythe; Gabriela B Gomez; Jared M Baeten; Grace John-Stewart; Carol Levin Journal: J Int AIDS Soc Date: 2019-07 Impact factor: 5.396